Please enable JS

Other Programs

Pipeline

Other Programs

Utilizing our proprietary MIDAS technology, we are developing inhibitors of key metalloenzymes in the areas of hospital-based fungal infections, oncology and orphan diseases. Similar to our experience in targeting fungal CYP51, we have been able to rapidly generate promising lead molecules in each of these programs that demonstrate significant improvements in selectivity as compared with other agents either in development or currently marketed for these conditions.